At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Orforglipron (drug), Placebo (drug)
- How long the study runs
- Study runs about 28 months (dates as stated)
- About the drug or intervention
- Orforglipron — drug: Administered orally. · Placebo — drug: Administered orally.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 6 Years to 17 Years
- Who
- All
- Number of participants
- 125
- Started
- 2024-11-18
- Last checked
- 2026-10
Plain English Summary
What is this study?
- • Testing a new treatment for obesity
- • Phase3 - 125 participants
- • The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants
Who can take part?
- • Ages 6 Years to 17 Years
- • Diagnosed with obesity
Where?
- • Barnsley - Barnsley Hospital NHS Foundation Trust
- • Bristol - Bristol Royal Hospital for Children
- • Cambridge - Addenbrookes Hospital
- • Dundee - Ninewells Hospital
- • +3 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
More detail
The PWMP establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. PWMP results will be reported when all the ISA's complete.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 6 Years - 17 Years
- Who can join: All genders
What the study is looking for
- ✓Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth...
- ✓hypertension
- ✓type 2 diabetes (T2D)
- ✓prediabetes
- ✓dyslipidemia
Who cannot take part
- ✗Have undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:
- ✗gastric bypass
- ✗sleeve gastrectomy
- ✗restrictive bariatric surgery, such as Lap-Band® gastric banding, or
- ✗any other procedure intended to result in weight reduction.
See the full criteria
Where Is This Study? (7 UK sites)
Barnsley Hospital NHS Foundation Trust
Barnsley S75 2EP, United Kingdom
Bristol Royal Hospital for Children
Bristol BS2 8BJ, United Kingdom
Addenbrookes Hospital
Cambridge CB2 0QQ, United Kingdom
Ninewells Hospital
Dundee DD1 9SY, United Kingdom
Northwick Park Hospital
Harrow HA1 3UJ, United Kingdom
Hull Royal Infirmary - MAIN
Hull HU3 2JZ, United Kingdom
Alder Hey Children's Hospital
Liverpool L14 5AB, United Kingdom
How to Get in Touch
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Sponsor contactCONTACT
Physicians interested in becoming principal investigators please contact
Sponsor contactCONTACT
